Patented small molecule inhibitors in the ubiquitin proteasome system
2007

Patented Small Molecule Inhibitors in the Ubiquitin Proteasome System

publication Evidence: moderate

Author Information

Author(s): Philippe Guédat, Frédéric Colland

Primary Institution: Hybrigenics SA

Hypothesis

The ubiquitin proteasome system (UPS) can be targeted for the development of new cancer therapies through patented small molecule inhibitors.

Conclusion

Recent advances in patented proteasome inhibitors show promise for treating multiple myeloma and other cancers.

Supporting Evidence

  • The approval of Velcade® (bortezomib) for multiple myeloma treatment establishes the UPS as a valid cancer target.
  • NPI-0052 has shown to outperform bortezomib in preclinical studies.
  • New classes of proteasome inhibitors are being developed with potential applications in various diseases.

Takeaway

Scientists are finding new ways to stop cancer by using special drugs that target a system in our cells that helps break down proteins.

Methodology

The review assesses advances in the discovery and development of patented small-molecule inhibitors targeting components of the UPS.

Limitations

The review does not consider patents on methods or target validation in the UPS.

Digital Object Identifier (DOI)

10.1186/1471-2091-8-S1-S14

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication